Publications

Found 42 results

Filters: Author is Seaman, Michael S [Clear All Filters]

2017

Caskey M, Schoofs T, Gruell H, Settler A, Karagounis T, Kreider EF, Murrell B, Pfeifer N, Nogueira L, Oliveira TY et al.. 2017. Antibody 10-1074 suppresses viremia in HIV-1-infected individuals.. Nat Med.

Freund NT, Wang H, Scharf L, Nogueira L, Horwitz JA, Bar-On Y, Golijanin J, Sievers SA, Sok D, Cai H et al.. 2017. Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller.. Sci Transl Med. 9(373)

Nishimura Y, Gautam R, Chun T-W, Sadjadpour R, Foulds KE, Shingai M, Klein F, Gazumyan A, Golijanin J, Donaldson M et al.. 2017. Early antibody therapy can induce long-lasting immunity to SHIV.. Nature.

2016

Bournazos S, Gazumyan A, Seaman MS, Nussenzweig MC, Ravetch JV. 2016. Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency.. Cell. 165(7):1609-20.

Scheid JF, Horwitz JA, Bar-On Y, Kreider EF, Lu C-L, Lorenzi JCC, Feldmann A, Braunschweig M, Nogueira L, Oliveira T et al.. 2016. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption.. Nature.

Schoofs T, Klein F, Braunschweig M, Kreider EF, Feldmann A, Nogueira L, Oliveira T, Lorenzi JCC, Parrish EH, Learn GH et al.. 2016. HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1.. Science. 352(6288):997-1001.

McGuire AT, Gray MD, Dosenovic P, Gitlin AD, Freund NT, Petersen J, Correnti C, Johnsen W, Kegel R, Stuart AB et al.. 2016. Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice.. Nat Commun. 7:10618.

2015

Gardner MR, Kattenhorn LM, Kondur HR, von Schaewen M, Dorfman T, Chiang JJ, Haworth KG, Decker JM, Alpert MD, Bailey CC et al.. 2015. AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges.. Nature. 519(7541):87-91.

Ranasinghe S, Soghoian DZ, Lindqvist M, Ghebremichael M, Donaghey F, Carrington M, Seaman MS, Kaufmann DE, Walker BD, Porichis F. 2015. HIV-1 antibody neutralization breadth is associated with enhanced HIV-specific CD4+ T cell responses.. J Virol.

Sanders RW, van Gils MJ, Derking R, Sok D, Ketas TJ, Burger JA, Ozorowski G, Cupo A, Simonich C, Goo L et al.. 2015. HIV-1 neutralizing antibodies induced by native-like envelope trimers.. Science.

Dosenovic P, von Boehmer L, Escolano A, Jardine J, Freund NT, Gitlin AD, McGuire AT, Kulp DW, Oliveira T, Scharf L et al.. 2015. Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice.. Cell. 161(7):1505-15.

McCoy LE, Falkowska E, Doores KJ, Le K, Sok D, van Gils MJ, Euler Z, Burger JA, Seaman MS, Sanders RW et al.. 2015. Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies.. PLoS Pathog. 11(8):e1005110.

Galimidi RP, Klein JS, Politzer MS, Bai S, Seaman MS, Nussenzweig MC, West AP, Bjorkman PJ. 2015. Intra-Spike Crosslinking Overcomes Antibody Evasion by HIV-1.. Cell. 160(3):433-46.

Freund NT, Horwitz JA, Nogueira L, Sievers SA, Scharf L, Scheid JF, Gazumyan A, Liu C, Velinzon K, Goldenthal A et al.. 2015. A New Glycan-Dependent CD4-Binding Site Neutralizing Antibody Exerts Pressure on HIV-1 In Vivo.. PLoS Pathog. 11(10):e1005238.

Caskey M, Klein F, Lorenzi JCC, Seaman MS, West AP, Buckley N, Kremer G, Nogueira L, Braunschweig M, Scheid JF et al.. 2015. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.. Nature. 522(7557):487-91.

2014

Scharf L, Scheid JF, Lee J H, West AP, Chen C, Gao H, Gnanapragasam PNP, Mares R, Seaman MS, Ward AB et al.. 2014. Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike.. Cell Rep. 7(3):785-95.

Halper-Stromberg A, Lu C-L, Klein F, Horwitz JA, Bournazos S, Nogueira L, Eisenreich TR, Liu C, Gazumyan A, Schaefer U et al.. 2014. Broadly Neutralizing Antibodies and Viral Inducers Decrease Rebound from HIV-1 Latent Reservoirs in Humanized Mice.. Cell.

Bournazos S, Klein F, Pietzsch J, Seaman MS, Nussenzweig MC, Ravetch JV. 2014. Broadly Neutralizing Anti-HIV-1 Antibodies Require Fc Effector Functions for In Vivo Activity.. Cell. 158(6):1243-53.

Falkowska E, Le KM, Ramos A, Doores KJ, Lee J H, Blattner C, Ramirez A, Derking R, van Gils MJ, Liang C-H et al.. 2014. Broadly Neutralizing HIV Antibodies Define a Glycan-Dependent Epitope on the Prefusion Conformation of gp41 on Cleaved Envelope Trimers.. Immunity. 40(5):657-68.

Klein F, Nogueira L, Nishimura Y, Phad G, West AP, Halper-Stromberg A, Horwitz JA, Gazumyan A, Liu C, Eisenreich TR et al.. 2014. Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants.. J Exp Med. 211(12):2361-72.

Sok D, Doores KJ, Briney B, Le KM, Saye-Francisco KL, Ramos A, Kulp DW, Julien J-P, Menis S, Wickramasinghe L et al.. 2014. Promiscuous Glycan Site Recognition by Antibodies to the High-Mannose Patch of gp120 Broadens Neutralization of HIV.. Sci Transl Med. 6(236):236ra63.

Sok D, van Gils MJ, Pauthner M, Julien J-P, Saye-Francisco KL, Hsueh J, Briney B, Lee J H, Le KM, Lee PS et al.. 2014. Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex.. Proc Natl Acad Sci U S A. 111(49):17624-9.

2013

Gavrilyuk J, Ban H, Uehara H, Sirk SJ, Saye-Francisco K, Cuevas A, Zablowsky E, Oza A, Seaman MS, Burton DR et al.. 2013. Antibody conjugation approach enhances breadth and potency of neutralization of anti-HIV-1 antibodies and CD4-IgG.. J Virol. 87(9):4985-93.

Ferguson AL, Falkowska E, Walker LM, Seaman MS, Burton DR, Chakraborty AK. 2013. Computational prediction of broadly neutralizing HIV-1 antibody epitopes from neutralization activity data.. PLoS One. 8(12):e80562.

Sok D, Laserson U, Laserson J, Liu Y, Vigneault F, Julien J-P, Briney B, Ramos A, Saye KF, Le K et al.. 2013. The effects of somatic hypermutation on neutralization and binding in the PGT121 family of broadly neutralizing HIV antibodies.. PLoS Pathog. 9(11):e1003754.

Pages